<DOC>
	<DOCNO>NCT02172222</DOCNO>
	<brief_summary>Study investigate relative bioavailability BI 10773 linagliptin concomitant multiple oral administration 50 mg BI 10773 tablet 5 mg linagliptin comparison 50 mg BI 10773 5 mg linagliptin give alone .</brief_summary>
	<brief_title>Relative Bioavailability BI 10773 Linagliptin Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Healthy male volunteer accord follow criterion : Based upon complete medical history physical examination include vital sign ( BP ( blood pressure ) , PR ( pulse rate ) ) , 12lead ECG ( electrocardiogram ) clinical laboratory test Age 18 50 year ( inclusive ) BMI 18.5 29.9 kg/m2 ( inclusive ) Signed date write informed consent prior admission study accordance GCP ( Good Clinical Practice ) local legislation . Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 30 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>